YG-1699 is under clinical development by Youngene Therapeutics and currently in Phase I for Congestive Heart Failure (Heart Failure). According to GlobalData, Phase I drugs for Congestive Heart Failure (Heart Failure) have an 80% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. GlobalData’s report assesses how YG-1699’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
Smarter leaders trust GlobalData
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
YG-1699 overview
YG-1699 is under development for the treatment of diabetes accompanied by chronic kidney disease, diabetes type 1, type 2 diabetes, heart failure and cystic fibrosis. The drug candidate acts by targeting sodium glucose transporter 1 (SGLT1) and sodium glucose transporter 2 (SGLT2). It is administered through oral route.
For a complete picture of YG-1699’s drug-specific PTSR and LoA scores, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.
